SIO Master Class: Y90

Join us virtually this fall for the exciting and informative SIO Master Class: Y90 from 1-2 October 2020. The SIO Y90 Master Class is a two-day virtual event where thought leaders in interventional oncology will gather to learn about the latest research and techniques using Y90 radioembolization.

Attendees will have the opportunity to engage in tumor boards, Q&A, and virtual roundtable discussions. The sessions are especially designed for physicians, medical students, fellows and post-grads within the cancer field who are specifically interested in interventional oncology/radiology and learning more about the Y90 product for cancer therapy. It is also intended for interventional radiologists who treat patients with hepatic malignancies.


SIO Members: $300.00
SIO Non-Members: $750.00
Registration & Membership Bundle: $600.00


Commercial Support Acknowledgment
This activity is supported by an educational grant from Sirtex.

Jointly provided by The France Foundation and The Society of Interventional Oncology

france.png     sio.png

About Yttrium-90 (Y90):

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Patients with early stage disease are eligible for curative therapies including surgical resection or liver transplant although most patients are diagnosed with advanced disease.

Yttrium-90 (Y90) microspheres are used for radioembolization procedures for patients with unresectable hepatocellular carcinoma and has demonstrated organ sparing benefits, proven efficacy in very advanced stages of HCC and good long term outcomes. Currently, there are two approved available Y-90 devices for administration and numerous ongoing trials aimed at exploring the current and future utility of radioembolization in hepatic malignancies. Despite it’s efficacy, intra-arterial Y90 is an under-utilized therapy and education on appropriate use remains scarce. This activity is developed to educate clinicians on this important modality to treat hepatic malignancies.